[
  {
    "id": "2fc6018b-33b8-4afa-a782-59a71443ea9a",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer",
    "abstract": "In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients.",
    "published": "2025-12-18",
    "authors": [
      "Thomas Powles, Ariel G. Kann, Daniel Castellano, Marine Gross-Goupil, Hiroyuki Nishiyama, Sergio Bracarda, Jørgen Bjerggaard Jensen, Lydia Makaroff, Shusuan Jiang, Ja Hyeon Ku, Se Hoon Park, Oscar Reig Torras, Dingwei Ye, Marco Maruzzo, Andrea Necchi, Rafael Morales-Barrera, Emilio Francesco Giunta, Jae Lyun Lee, Giampaolo Tortora, Yüksel Ürün, Lukasz Dolowy, Dilek Erdem, Alvaro Pinto, Fabricio Grando, Wei Zou, Zoe June Assaf, Jacqueline Vuky, Viraj Degaonkar, Elizabeth E. Steinberg, Joaquim Bellmunt, Jürgen E. Gschwend, the IMvigor011 Investigators*"
    ],
    "doi": "10.1056/NEJMoa2511885",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2511885?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "ceae9155-8b84-45d5-be1d-d1617e384d12",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Noninferiority of One HPV Vaccine Dose to Two Doses",
    "abstract": "In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection.",
    "published": "2025-12-18",
    "authors": [
      "Aimée R. Kreimer, Carolina Porras, Danping Liu, Allan Hildesheim, Loretto J. Carvajal, Rebeca Ocampo, Byron Romero, Mitchell H. Gail, Bernal Cortes, Monica S. Sierra, Karla Coronado, Joshua Sampson, Carolina Coto, Casey L. Dagnall, Daniela Mora, Troy J. Kemp, Michael Zuniga, Ligia A. Pinto, Gloriana Barrientos, John Schussler, Yenory Estrada, Cristian Montero, Carlos Avila, Dave Ruggieri, Jean T. Cyr, Stephen Chanock, Douglas R. Lowy, John T. Schiller, Rolando Herrero"
    ],
    "doi": "10.1056/NEJMoa2506765",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2506765?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "ad4b79a0-5408-4c1f-9844-848fcf9ab709",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection",
    "abstract": "Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial...",
    "published": "2025-12-18",
    "authors": [
      "Ruanne V. Barnabas"
    ],
    "doi": "10.1056/NEJMe2515387",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMe2515387?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "eae9edaf-3133-409f-a7fc-85d31ea88821",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Reducing Tobacco Use Worldwide: The Epidemic of Tobacco Harms among People with Mental Health Conditions",
    "abstract": "High rates of tobacco use among people with mental health conditions contribute to their increased morbidity and mortality, but tobacco cessation interventions can be effective in this population.",
    "published": "2025-12-18",
    "authors": [
      "Simon Gilbody, Garima Bhatt, Krishna P. Muliyala"
    ],
    "doi": "10.1056/NEJMp2500491",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMp2500491?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "8a01b56a-f380-44e6-b7c5-928146ec42b4",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Merkel-Cell Carcinoma",
    "abstract": "A 72-year-old woman presented with a 3.5-month history of an enlarging, painless lump on her cheek. Examination showed a dome-shaped, reddish nodule on the left cheek, with a shiny surface and central hemorrhagic crust.",
    "published": "2025-12-18",
    "authors": [
      "Zunaid Ahmed, Willem Visser"
    ],
    "doi": "10.1056/NEJMicm2513302",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMicm2513302?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b3892784-48c0-47ca-97f8-5e8ea4694d17",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "ctDNA-Guided Therapy in Bladder Cancer — Ready?",
    "abstract": "Liquid-biopsy analysis for circulating tumor DNA (ctDNA) has the potential to transform cancer care through personalized, noninvasive disease monitoring. In bladder cancer, ctDNA is a strong prognostic biomarker after cystectomy and may guide adjuvant treatment decisions. Retrospective and prospective studies show that ctDNA positivity is linked to an increased risk...",
    "published": "2025-12-18",
    "authors": [
      "Lars Dyrskjøt"
    ],
    "doi": "10.1056/NEJMe2514185",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMe2514185?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "8f8e432e-9efe-474b-9602-df7a86f67875",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer",
    "abstract": "In HER2-expressing urothelial cancer, disitamab vedotin plus toripalimab doubled the median progression-free survival, increased the median overall survival, and reduced adverse events as compared with chemotherapy.",
    "published": "2025-12-11",
    "authors": [
      "Xinan Sheng, Gongqian Zeng, Cuijian Zhang, Qingyun Zhang, Jiasheng Bian, Haitao Niu, Jun Li, Yanxia Shi, Kai Yao, Bin Hu, Ziling Liu, Hong Liao, Zhixian Yu, Baiye Jin, Peng Zhao, Tiejun Yang, Xianling Liu, Yang Qin, Xueyi Xue, Xin Gou, Jian Huang, Jiang Gu, Xiaolong Qi, Lu Zhang, Guoxian Ma, Beisong Liu, Jianmin Fang, Shusuan Jiang, Zhisong He, Aiping Zhou, Jun Guo, the RC48-C016 Trial Investigators*"
    ],
    "doi": "10.1056/NEJMoa2511648",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2511648?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "585d7a38-462a-4fa9-a75d-75572453d51d",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Understanding How Aspirin Prevents Metastasis",
    "abstract": "A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2.",
    "published": "2025-12-11",
    "authors": [
      "Ruth E. Langley, John Burn"
    ],
    "doi": "10.1056/NEJMcibr2502386",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMcibr2502386?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "7b24e335-dc91-4e71-b825-c8072260075a",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Disitamab Vedotin plus Toripalimab — New Players in Urothelial Carcinoma",
    "abstract": "For decades, platinum-based chemotherapy was the standard first-line treatment for locally advanced or metastatic urothelial carcinoma.1 However, the treatment landscape in urothelial carcinoma has shifted with the advent of immune checkpoint inhibitors.2 Although immune checkpoint inhibitors were initially used as single agents after chemotherapy failure, combinations...",
    "published": "2025-12-11",
    "authors": [
      "Jens Bedke"
    ],
    "doi": "10.1056/NEJMe2514668",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMe2514668?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d3c53d2b-90aa-4653-a0be-986e5236ade9",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events",
    "abstract": "In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared.",
    "published": "2025-12-11",
    "authors": [
      "Yuxuan Wang, Howard L. Li, Chetan Bettegowda, Kenneth W. Kinzler, Nickolas Papadopoulos, Mark Yarchoan, Bert Vogelstein"
    ],
    "doi": "10.1056/NEJMc2513984",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMc2513984?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f6316cda-8b00-4957-8736-7999b39ab988",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer",
    "abstract": "In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease.",
    "published": "2025-12-10",
    "authors": [
      "Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Jame Abraham, Aleix Prat, Naoki Niikura, Seock-Ah Im, Wei Li, Huiping Li, Yongsheng Wang, Herui Yao, Sung-Bae Kim, Cui-zhi Geng, Wuilbert Rodriguez Pantigoso, Francisco Javier Ramírez Godinez, Chuangui Song, Yuan Ching Chang, Augusto Antoniazzi, Shin-Cheh Chen, Zhigao Li, Zbigniew Nowecki, Joline Lim, Elton Mathias, Yuta Sato, Wenjing Lu, Hanan Abdel-Monem, Michael Untch, Charles E. Geyer Jr., the DESTINY-Breast05 Trial Investigators*"
    ],
    "doi": "10.1056/NEJMoa2514661",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2514661?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "c020f688-bb3d-465e-b269-b777824f4bfd",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Ianalumab plus Eltrombopag in Immune Thrombocytopenia",
    "abstract": "In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo.",
    "published": "2025-12-09",
    "authors": [
      "Adam Cuker, Thomas Stauch, Nichola Cooper, Hanny Al-Samkari, Marc Michel, Waleed Ghanima, Patrick Urban, Justyna Fronczek, Matthew Foster, Marine Weill, Lei Zhang, Ming Hou, Thomas Zander, Azizan Sharif, Jing Sun, Uttam Kumar Nath, Roger Schutgens, Elena Rossi, Lien Deleu, Libor Červinek, Jae-Ho Yoon, Hung Chang, Theera Ruchutrakool, Masaki Iino, Tatsunori Goto, Francesco Zaja, the VAYHIT2 Investigators*"
    ],
    "doi": "10.1056/NEJMoa2515168",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2515168?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "a0dab8bf-b876-4f7f-a21c-a05fe3c13054",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma",
    "abstract": "In relapsed or refractory multiple myeloma, teclistamab plus daratumumab significantly prolonged progression-free survival as compared with DPd or DVd (83.4% vs. 29.7%) and had higher response rates.",
    "published": "2025-12-09",
    "authors": [
      "Luciano J. Costa, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu, Anne K. Mylin, Charlotte T. Hansen, Raphael Teipel, Britta Besemer, Meletios A. Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kim, Chang Ki Min, Paul Geerts, Elena Van Leeuwen-Segarceanu, Agata Tyczynska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodriguez-Otero, Joaquin Martinez-Lopez, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Deborah Briseno-Toomey, Lisa O’Rourke, Maria Rubin, Diego Vieyra, Lijuan Kang, Maria Victoria Mateos, the MajesTEC-3 Trial Investigators*"
    ],
    "doi": "10.1056/NEJMoa2514663",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2514663?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "9115cf79-44b4-4e29-bc3d-000d14fbfd87",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia",
    "abstract": "In relapsed or refractory T-cell acute lymphoblastic leukemia, off-the-shelf allogeneic base-edited CAR7 T cells mediated responses in 11 patients, enabling stem-cell transplantation in 9 patients in deep remission.",
    "published": "2025-12-08",
    "authors": [
      "Robert Chiesa, Christos Georgiadis, Hebatalla Rashed, Roland Preece, Prudence Hardefeldt, Jan Chu, Jemma Selvage, Avijeet Mishra, Batoul Ahmed, Stuart Adams, Rebecca Thomas, Kimberly Gilmour, Annie Etuk, Deborah Yallop, David O’Connor, Waseem Qasim, the Base-Edited CAR T Group*"
    ],
    "doi": "10.1056/NEJMoa2505478",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2505478?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "c59ef942-a189-4a1f-b27d-4d2c77f7277a",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B",
    "abstract": "Among men with hemophilia B, sustained endogenous factor IX expression and low annualized bleeding rates over the course of 5 years were seen after an infusion of etranacogene dezaparvovec.",
    "published": "2025-12-07",
    "authors": [
      "Steven W. Pipe, Wolfgang Miesbach, Michael Recht, Frank W.G. Leebeek, Nigel S. Key, Giancarlo Castaman, Susan Lattimore, Michiel Coppens, Sandra Le Quellec, Vaibhav Mahajan, Sean Gill, Douglass Drelich, Paul E. Monahan, the HOPE-B Study Group Investigators*"
    ],
    "doi": "10.1056/NEJMoa2514332",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2514332?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "9fbf89c7-a63d-4630-bc23-3b2f904e3dd2",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab",
    "abstract": "In drug-resistant extramedullary myeloma, dual treatment with talquetamab and teclistamab produced a response in 79% of patients, and 12-month overall survival was 74%; however, grade 3 or 4 adverse events were common.",
    "published": "2025-12-07",
    "authors": [
      "Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael P. Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey V. Matous, Laura Rosiñol, Koichi Onodera, Emma Scott, Christoph Heuck, Jenny Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Saad Z. Usmani, Yael C. Cohen, the RedirecTT-1 Investigators Study Group*"
    ],
    "doi": "10.1056/NEJMoa2514752",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2514752?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "da2171a4-fec7-4ba7-87af-4060654f4402",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Brief Report: Prime Editing for p47phox-Deficient Chronic Granulomatous Disease",
    "abstract": "In this study, gene editing with a prime editor was used to treat two persons with chronic granulomatous disease caused by a small deletion in the gene NCF1.",
    "published": "2025-12-07",
    "authors": [
      "Jennifer L. Gori, Elie Haddad, Haydar Frangoul, Donald B. Kohn, Emma C. Morris, Bradley N. Martin, Briana A. Deary, McKinley Nickerson, Rebecca L. Scholz, Isabel Fernandez, Karine Leveille, Suk See De Ravin, Elizabeth M. Kang, Marie Pierzynski, Tyra Estwick, Patricia Littel, Douglas B. Kuhns, Debra A. Long Priel, Pierre Teira, Stuart Turvey, Jordyn Arnold, Misty D. Evans, Meghann McManus, Ben Carpenter, David P. Waterman, Andrew V. Anzalone, Alexandria Petrusich, Christa E. Osuna, Tiernan T. O’Malley, Jacob Stewart-Ornstein, Jack M. Heath, Barrett J. Nehilla, Mohammed Asmal, Harry L. Malech"
    ],
    "doi": "10.1056/NEJMoa2509807",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2509807?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "689af84e-af0d-4e85-a9e6-40dbdbad5eb7",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia",
    "abstract": "In untreated chronic lymphocytic leukemia, fixed-duration venetoclax-based regimens were noninferior to continuous ibrutinib with regard to 3-year progression-free survival and were associated with higher MRD-negative rates.",
    "published": "2025-12-06",
    "authors": [
      "Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon P. Kater, Vesa Lindström, Mattias Mattsson, Carsten U. Niemann, Philipp B. Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian B. Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Anna Maria Frustaci, Lydia Scarfò, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek, the CLL17 Trial Investigators*"
    ],
    "doi": "10.1056/NEJMoa2515458",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2515458?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f5b75d30-5ef4-4758-9736-76df1d394454",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia",
    "abstract": "In patients with hereditary hemorrhagic telangiectasia, treatment with engasertib reduced nosebleed frequency and duration over 12 weeks, with mild reversible rash as the most common drug-related side effect.",
    "published": "2025-11-27",
    "authors": [
      "Hanny Al-Samkari, Josefien Hessels, Antoni Riera-Mestre, Sophie Dupuis-Girod, Thibaut Van Zele, Vicente Gómez del Olmo, Pamela G. Hodges, Raquel Torres-Iglesias, Roberto Bertè, Pierre Saint-Mezard, Hedvika Lazar, Nicholas Benedict, Debra Barker, Corrado Bernasconi, Damien Picard, Elisabetta Buscarini, Hans-Jurgen Mager"
    ],
    "doi": "10.1056/NEJMoa2504411",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2504411?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "64db5d9e-893d-401b-935e-3d302a12cc58",
    "source_feed": "https://onesearch-rss.nejm.org/api/specialty/rss?context=nejm&specialty=hematology-oncology",
    "journal": "The New England Journal of Medicine: Search Results in Hematology/Oncology",
    "title": "Case 34-2025: A 57-Year-Old Woman with Visual Disturbances and Right-Arm Shaking",
    "abstract": "A 57-year-old woman with a history of subarachnoid hemorrhage was admitted to the hospital because of visual disturbances involving the right visual field, as well as episodes of shaking of the right arm and leg. A diagnosis was made.",
    "published": "2025-11-27",
    "authors": [
      "Nancy Wang, Shenghua Zhu, Aman B. Patel, Donald P. Lawrence, Anthony R. Russo"
    ],
    "doi": "10.1056/NEJMcpc2513534",
    "link": "https://www.nejm.org/doi/full/10.1056/NEJMcpc2513534?rss=searchAndBrowse",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "guidislink",
      "id",
      "link",
      "links",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "940b6a3e-e5bb-465a-b8a5-64adedcf30be",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Editorial] Making prostate cancer screening fit for purpose",
    "abstract": "Prostate cancer incidence is predicted to double to 2·9 million cases by 2040. Men diagnosed with clinically significant prostate cancer have many effective treatment options, but questions remain regarding the best diagnostic pathway. The value of population-based prostate cancer screening using a prostate-specific antigen (PSA) threshold, for example, is long-debated and is not universally recommended because of concerns around the risk of overdiagnosis and overtreatment.",
    "published": "2025-12",
    "authors": [
      "The Lancet Oncology"
    ],
    "doi": "10.1016/S1470-2045(25)00672-2",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00672-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b4a2a7d5-ff18-4bcb-8ec4-b32116c70460",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Defining eligibility for lung cancer screening based on individual risk",
    "abstract": "Implementation of lung cancer screening is advancing globally, and most countries use categorical eligibility criteria resembling those from randomised low-dose CT screening trials. For example, the US Preventive Services Task Force (USPSTF) requires age 50–80 years, at least 20 pack-years smoked, and 15 years or less of cessation. However, beginning in 2013, studies suggested that defining eligibility using individual lung cancer risk prediction models would yield more lung cancer deaths prevented per population screened.",
    "published": "2025-11-10T23:30:01Z",
    "authors": [
      "Hilary A Robbins, Mattias Johansson"
    ],
    "doi": "10.1016/S1470-2045(25)00537-6",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00537-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "32b4db7e-b7c3-4990-b4dc-40dcdec8519c",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Pirfenidone: a new option for radiation-induced lung injury?",
    "abstract": "Radiation-induced lung injury is a clinically significant complication induced by thoracic radiotherapy.1 10–20% of patients present with signs of radiation-induced lung injury, which vary widely according to grade and type of cancer and duration of treatment.2",
    "published": "2025-11-06T23:30:01Z",
    "authors": [
      "Elisabetta Balestro"
    ],
    "doi": "10.1016/S1470-2045(25)00544-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00544-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "4e0f7c77-2118-4b52-aaf6-e4241b0b659f",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom?",
    "abstract": "In The Lancet Oncology, Jing Yuan and colleagues present updated results from the SYSUCC-001 trial, evaluating extended adjuvant endocrine therapy with a year of twice daily (metronomic) capecitabine compared with observation in early-stage triple-negative breast cancer following standard chemotherapy.1,2 This post-hoc analysis includes data from 420 of the 434 patients in the trial. The findings confirm the benefit of extended adjuvant capecitabine compared with observation, with statistically significant, double-digit improvements in disease-free survival, distant disease-free survival, and locoregional recurrence-free survival at 10 years.",
    "published": "2025-12",
    "authors": [
      "William M Sikov"
    ],
    "doi": "10.1016/S1470-2045(25)00621-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00621-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "e503a950-f392-4ee0-8141-b3746bfa6e5e",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Of surrogate endpoints, shortcuts, and safety",
    "abstract": "Adjuvant and neoadjuvant systemic drug therapy prevents recurrence and premature death in patients with breast cancer by treating undetectable micrometastatic disease.1 For less toxic treatments, prevention of metastases alone can justify therapy because patients should experience improved quality of life without metastases, but for more toxic or risky treatments improved overall survival might be required.2 When improving overall survival is the agreed-upon goal, both regulators and clinicians must balance the harms from delaying access to treatments later confirmed as improving overall survival (leaving aside the question of magnitude) against the harms of over-treating many patients who they later learn derived no improvement in survival.",
    "published": "2025-12",
    "authors": [
      "Clifford A Hudis, Elizabeth Garrett-Mayer"
    ],
    "doi": "10.1016/S1470-2045(25)00663-1",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00663-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "1621b62f-c902-4a68-8e9a-08e3d64092cd",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Evolution in rectal cancer management",
    "abstract": "Non-operative management after a clinical complete response following neoadjuvant treatment in rectal cancer, often referred to as opportunistic non-operative management rather than intentional non-operative management (ie, up-front treatment for early-stage patients with the aim of non-operative management), is increasingly being implemented. Provided meticulous follow-up, data suggest that non-operative management is feasible, safe, and associated with favourable overall survival.1 However, challenges remain, such as response assessment after neoadjuvant therapy,2 management of near clinical complete response,3 and whether distant control is affected.",
    "published": "2025-12",
    "authors": [
      "Per J Nilsson"
    ],
    "doi": "10.1016/S1470-2045(25)00600-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00600-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "ca54eb2d-2914-4418-acda-a65bd408e78a",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice",
    "abstract": "Improved molecular classification of glioma has allowed identification of defined patient subgroups with prolonged survival outcomes and the potential for alternative management plans.1,2 Specifically for newly diagnosed patients with lower grade glioma (WHO grade 2–3) harbouring the IDH mutation, initial neurosurgical decision making can be complex due to the balance of optimising disease control and avoidance of long-term neurological morbidity. Additionally, these tumours present with varying neuroradiological appearance related to volume, morphology, and neuroanatomical site, which means interventions require individualisation based on these parameters.",
    "published": "2025-12",
    "authors": [
      "Michael Back"
    ],
    "doi": "10.1016/S1470-2045(25)00592-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00592-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "31e2af85-bb86-4be6-beb8-24b5a76f7615",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Focused ultrasound treatments could increase survival in individuals with glioma",
    "abstract": "Non-invasive and targeted transcranial focused ultrasound (FUS) treatments combined with systemically administered microbubbles enhance the delivered chemotherapeutic dose within brain tumours, due to reversible blood–brain barrier opening (BBBO).1–3 In preclinical studies, increased drug delivery has led to measurable overall survival benefit in animal models of high-grade glioma.4–7 However, to date, there has been no evidence of prolonged overall survival in individuals with glioma.",
    "published": "2025-12",
    "authors": [
      "Antonios N Pouliopoulos"
    ],
    "doi": "10.1016/S1470-2045(25)00552-2",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00552-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "304c0c30-f6cb-4e75-bb22-e6b7afc220b4",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Targeting IDH mutation: another milestone, but not the finish line",
    "abstract": "Targeted therapy has entered the stage of glioma management. Mutated isocitrate dehydrogenase (IDH) is the molecular hallmark of WHO grade 2 diffuse low-grade gliomas. In The Lancet Oncology, Timothy F Cloughesy and colleagues compared the mutated IDH inhibitor vorasidenib with placebo for diffuse low-grade gliomas without high-risk features, with 6 months' additional follow-up.1 As expected with the short additional follow-up, this study supports the results of progression-free survival, time to next intervention, and adverse events from the phase 3 trial (INDIGO).",
    "published": "2025-10-29T23:30:02Z",
    "authors": [
      "Asgeir S Jakola, Isabelle Rydén"
    ],
    "doi": "10.1016/S1470-2045(25)00491-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00491-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "13d82397-b690-429f-83cf-3c4a226164a6",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] Re-establishing human-centred care",
    "abstract": "In 2021, the Global Institute of Psychosocial, Palliative, and End-of-Life Care (University of Toronto, Canada) in collaboration with the Institute of Cancer Policy (King's College London, UK) launched a project called Biomedicine and the Soul of Medicine: Optimising the Balance. As part of this project, a multidisciplinary symposium held over 3 days on Palliative Care, Culture, and the Clinic brought together more than 600 registrants from over 60 countries to explore humanistic and culturally relevant dimensions of cancer care, particularly for patients with advanced disease.",
    "published": "2025-11-02T23:30:02Z",
    "authors": [
      "Cheryl Reeves, David Collingridge"
    ],
    "doi": "10.1016/S1470-2045(25)00604-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00604-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "dba474f4-d394-41de-ab34-6d777d6909fa",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home",
    "abstract": "The UK has had serial national cancer control plans (NCCPs) since 1997. Early progress was undeniable, but momentum has waned over the past 15 years, with considerable slippage in cancer survival rankings (eg, the UK is ranked 28th of 33 countries, with similar wealth and income, for 5-year survival with lung and stomach cancer)1 and very poor performance in the International Cancer Benchmarking Partnership cancer policy scorecard.2 At a meeting convened by St George's House (Windsor, UK) in September, 2025, international experts shared experiences of designing and implementing their own plans.",
    "published": "2025-11-06T23:30:03Z",
    "authors": [
      "Mark Lawler, Cary Adams, Eduardo Pisani, Yannick Romero, Sarah Quinlan, Pat Price"
    ],
    "doi": "10.1016/S1470-2045(25)00650-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00650-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "3d2583a8-0af0-47c2-8ecc-ecb20e9a923d",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Comment] The paradox of generics: broader access, less freedom",
    "abstract": "The Italian National Health Service is founded on universal coverage and equal access to care.1 In this context, sustainability is not optional, but structural; innovative treatments must coexist with responsible use of constrained financial resources. In oncology, where novel therapies have improved outcomes but also driven up costs, generic drugs represent a crucial tool.2 When patent protection expires, bioequivalent formulations can be marketed at lower prices, enabling systems to reduce expenditure on established therapies and reallocate resources to innovation.",
    "published": "2025-12",
    "authors": [
      "Giandomenico Roviello"
    ],
    "doi": "10.1016/S1470-2045(25)00613-8",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00613-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d68e88ee-dcfc-49f5-a5fa-17a2b9e8e79c",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] SunRISe-4 perioperative safety and TURBT stratification",
    "abstract": "We read with great interest the interim analysis of the SunRISe-4 trial by Andrea Necchi and colleagues.1 This study assessed the efficacy and safety of neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy.1 The authors reported a 42% pathological complete response rate with manageable toxicity, underscoring the potential to combine intravesical gemcitabine delivery with PD-1 blockade. Although these findings expand treatment options for cisplatin-ineligible patients, we highlight two points to enhance interpretability and clinical translation.",
    "published": "2025-12",
    "authors": [
      "Wei Luo, Sinan Yang, Chengwei Bi, Yong Yang, Zhiyu Shi"
    ],
    "doi": "10.1016/S1470-2045(25)00553-4",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00553-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "32aca6b4-faa7-4115-82d4-d9e63e9431db",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] SunRISe-4 perioperative safety and TURBT stratification – Authors' reply",
    "abstract": "We thank Wei Luo and colleagues for their insightful comments on our Article.1 We would like to offer some clarifications on the points raised.",
    "published": "2025-12",
    "authors": [
      "Andrea Necchi, Hind Stitou, Sumeet Bhanvadia, Sarah P Psutka"
    ],
    "doi": "10.1016/S1470-2045(25)00671-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00671-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "4563f9ff-ab4c-44d2-8014-b3accc8771d5",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] SBRT in oligometastatic castration-resistant prostate cancer",
    "abstract": "The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy (SBRT) with androgen receptor pathway inhibitors (ARPIs) in oligometastatic castration-resistant prostate cancer (mCRPC). This study is the second randomised trial, after the ARTO trial,2 to evaluate this combination. Both PCS-9 and ARTO showed improved radiographical progression-free survival with SBRT. However, a significant biochemical response benefit was only observed in the ARTO study, possibly reflecting differences in disease burden (baseline prostate-specific antigen was 3·4 ng/mL in ARTO vs ~10 ng/mL in PCS-9) and imaging strategies, with molecular imaging in ARTO likely identifying earlier disease.",
    "published": "2025-12",
    "authors": [
      "Vérane Achard, Pierre Blanchard, David Pasquier, Paul Sargos"
    ],
    "doi": "10.1016/S1470-2045(25)00565-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00565-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "e2243e88-7158-42b9-8c9f-455fcc5758ef",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials",
    "abstract": "We read with interest the Article by Daniel Ma and colleagues in The Lancet Oncology.1 Ma and colleagues should be congratulated on completing a randomised trial of de-escalated radiotherapy in patients with p16-positive oropharyngeal squamous cell carcinoma. The authors report progression-free survival, local regional control, freedom from distant metastases, and overall survival as secondary endpoints. The de-escalation protocol resulted in a reduction in progression-free survival, local regional control, and systemic control in patients who received de-escalated treatment with extracapsular extension compared with patients who received standard of care.",
    "published": "2025-12",
    "authors": [
      "Jessica T Lovett, Michael T Wotman, Marshall Posner"
    ],
    "doi": "10.1016/S1470-2045(25)00616-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00616-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "ececc177-5922-438b-90a2-3eaceb3e280c",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials – Authors' reply",
    "abstract": "We appreciate the important points raised by Jessica T Lovett and colleagues regarding p16 immunohistochemistry as a surrogate for HPV status in oropharyngeal squamous cell carcinoma in de-escalation studies such as MC1675.1 As they noted, the prognostic implications of p16 and HPV discordance have been previously analysed, such as in a multinational study by Mehanna and colleagues.2 Patients who were p16-positive and HPV-negative had an increased rate of cancer recurrence (hazard ratio 1·92, 95% CI 1·42–2·60).",
    "published": "2025-12",
    "authors": [
      "David M Routman, James S Lewis, Daniel J Ma"
    ],
    "doi": "10.1016/S1470-2045(25)00655-2",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00655-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "fa4131c0-da94-4e7f-9dde-68d4954177e9",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Corrections] Correction to Lancet Oncol 2024; 25: 1038–52",
    "abstract": "Allaf ME, Kim S-E, Master V, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 2024; 25: 1038–52—In this Article, some of the numbers of patients in the Results and figure 1 have been corrected. The appendix has also been corrected. These corrections have been made to the online version as of Nov 24, 2025.",
    "published": "2025-12",
    "authors": [],
    "doi": "10.1016/S1470-2045(25)00522-4",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00522-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "54ee455d-00ef-4f7b-b77c-7878c763aeaf",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Corrections] Correction to Lancet Oncol 2025; 26: 1443–53",
    "abstract": "Di Federico A, Stumpo S, Mantuano F, et al. Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis. Lancet Oncol 2025; 26: 1443–53—In figure 4A of this Article, the p value should have read p=0·20, and in figure 5A, the p value should have read p=0·012. These corrections have been made to the online version as of Nov 24, 2025.",
    "published": "2025-12",
    "authors": [],
    "doi": "10.1016/S1470-2045(25)00668-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00668-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "fef6e75a-d663-4f70-966e-c097ba612111",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] ESMO Congress 2025",
    "abstract": "Sara A Hurvitz (Fred Hutch Cancer Center, Seattle, WA, USA) and colleagues presented results from the randomised, open-label, phase 3, VIKTORIA-1 trial in 392 patients with HR+/HER2- advanced breast cancer. Medium progression-free survival was 9·3 months in patients receiving the triplet combination of gedatolisib (180 mg, intravenous, once weekly for 3 weeks), fulvestrant (500 mg, intramuscular, every 2 weeks [cycle 1] then every 4 weeks) and palbociclib (125 mg, once daily for 21 days) compared with 2·0 months (hazard ratio [HR] 0·24; 95% CI 0·17–0·35; p<0·0001) for patients receiving fulvestrant alone and 7·4 months (HR 0·33; 0·24–0·48; p<0·0001) for those receiving the doublet combination of gedatolisib plus fulvestrant.",
    "published": "2025-10-23T22:30:01Z",
    "authors": [
      "David Collingridge, Cheryl Lai, Allison Landman, Jamie Prowse, Cheryl Reeves"
    ],
    "doi": "10.1016/S1470-2045(25)00644-8",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00644-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "f3ec64f9-2e52-429f-8b72-74c4e6006581",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] Eastern Mediterranean Region backs Cairo Call on breast cancer",
    "abstract": "Health ministers in the Eastern Mediterranean region have officially adopted the Cairo Call to Action on Breast Cancer, uniting governments in the region behind a shared framework to address long-standing inequities in cancer care. The agreement outlines priorities to strengthen primary care screening, improve diagnostic and treatment services, expand psychosocial support, and integrate cancer data systems.",
    "published": "2025-10-23T22:30:01Z",
    "authors": [
      "Paul Adepoju"
    ],
    "doi": "10.1016/S1470-2045(25)00645-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00645-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "ceab2865-dfa2-488f-a9be-bf24af46ac1f",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] New Zealand extends breast cancer screening to 70–74-year-olds",
    "abstract": "As of Oct 15, 2025, New Zealand has, begun a nationwide extension to its breast cancer screening programme, which will now include women aged 70–74 years as well as those already eligible (aged 45–69 years). This will mean tens of thousands more women will be able to access free mammograms once every 2 years, beginning with those aged 70 and 74 years and then expanded over a 4-year rollout to include women aged 71, 72, and 73.",
    "published": "2025-10-23T22:30:01Z",
    "authors": [
      "Tony Kirby"
    ],
    "doi": "10.1016/S1470-2045(25)00646-1",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00646-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "d3d4aeb4-6d98-47d2-81b9-84c0a0765d48",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] Europe's Beating Cancer Plan delayed by “legislative inaction”",
    "abstract": "The success of Europe's Beating Cancer Plan (EBCP) is at risk of being undermined by slow progress on alcohol, tobacco, and nutrition control, according to an implementation findings study published on Oct 20, 2025.",
    "published": "2025-10-30T23:30:01Z",
    "authors": [
      "Elizabeth Gourd"
    ],
    "doi": "10.1016/S1470-2045(25)00657-6",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00657-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "756f1002-af60-4e79-b98d-4d928c6a2958",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] More e-cigarette users than cigarette smokers for the first time in the UK",
    "abstract": "The number of adults using e-cigarettes or vapes has exceeded the number of cigarette smokers in the UK for the first time, according to figures released on Nov 4, 2025, from the Office for National Statistics.",
    "published": "2025-11-13T23:30:01Z",
    "authors": [
      "Manjulika Das"
    ],
    "doi": "10.1016/S1470-2045(25)00676-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00676-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "c09aefdf-5b5c-4949-a46e-fb3b72939275",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[News] Government shutdown and Medicare changes impact cancer care in the USA",
    "abstract": "The effects of Medicare funding cuts and the longest ever shutdown of the US Federal Government have slowed momentum to a standstill in cancer prevention, screening, and treatment, warned the Association of American Cancer Institutes (AACI), which represents more than 100 academic and freestanding cancer centres in the USA and Canada.",
    "published": "2025-11-13T23:30:01Z",
    "authors": [
      "Sharmila Devi"
    ],
    "doi": "10.1016/S1470-2045(25)00677-1",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00677-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "5e3357e6-8314-4fad-825a-f881f2c1294e",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Perspectives] Cancer and comedy: a review of three stand-up specials",
    "abstract": "A cancer diagnosis does not leave much room for humour, but this year I saw three stand-up comedians who found plenty to talk about and took to the stage to share it with London audiences.",
    "published": "2025-12",
    "authors": [
      "Joseph Moody"
    ],
    "doi": "10.1016/S1470-2045(25)00673-4",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00673-4/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "eca4a266-dc59-46b0-a18b-43b600ba8858",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Perspectives] Cancer revolution: science, innovation, and hope",
    "abstract": "A stone's throw from Dublin's Merrion Square, where medical luminaries such as William Stokes and William Wilde plied their craft, stands the airy Georgian structure of the St Stephen's Green Centre. Typically housing an assortment of boutiques and galleries, it is, until Oct 31, 2025, hosting something more unusual, Cancer Revolution: Science, Innovation and Hope, a major new exhibition by Breakthrough Cancer Research.",
    "published": "2025-12",
    "authors": [
      "David Robert Grimes"
    ],
    "doi": "10.1016/S1470-2045(25)00674-6",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00674-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "b475be5d-ac85-435e-8a5f-4897cc6fed1d",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Perspectives] Humour in the face of hardship",
    "abstract": "Cancer—It Could Be Worse? (self-published, 2025) is T Fronks’ first book and an energetic, light-hearted addition to the cancer autobiography genre. Fronks, who lives in North Wales, UK, intersperses humorous and optimistic prose with over 50 witty poems and illustrations that she composed during her experience with breast cancer. The memoir presents a bank of enjoyable analogical descriptions and cultural references, from Star Wars to The Muppets, as well as useful practical advice surrounding all things cancer, family, and self-help.",
    "published": "2025-12",
    "authors": [
      "Daniel Mellor"
    ],
    "doi": "10.1016/S1470-2045(25)00675-8",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00675-8/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "1c6200ca-2a19-4899-93f8-449b165bd3ce",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Perspectives] When healing means letting go",
    "abstract": "I once believed that healing meant curing—that a good doctor must fight relentlessly against disease, offering every patient another chance, another line of therapy, another sliver of hope. My instinct was always to do more. But one patient taught me that sometimes, the truest form of healing begins when we learn to let go.",
    "published": "2025-12",
    "authors": [
      "Chinchu Babu"
    ],
    "doi": "10.1016/S1470-2045(25)00659-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00659-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "34d43d3b-6bb2-4037-8e57-ca0d4b56305f",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study",
    "abstract": "Participant selection using the PLCOm2012 risk prediction model with a 6-year risk of at least 1·58% cutoff is more efficient and effective in detecting lung cancer than the NELSON criteria and should therefore be implemented in lung cancer screening programmes.",
    "published": "2025-11-10T23:30:01Z",
    "authors": [
      "Jens Vogel-Claussen, Benjamin-Alexander Bollmann, Katharina May, Susanne Stiebeler, Sabine Dettmer, Anton Faron, Alexander Kuhlmann, Gerald Schmid-Bindert, Rudolf Kaaks, Jörg Barkhausen, Sabine Bohnet, Martin Reck, HANSE investigators"
    ],
    "doi": "10.1016/S1470-2045(25)00490-5",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00490-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "c166c9ff-2d33-45e0-96e3-06b41d1cb9ae",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial",
    "abstract": "Pirfenidone in combination with glucocorticoids provides a potential therapeutic strategy for grade 2 or grade 3 radiation-induced lung injury, addressing the unmet clinical need for effective antifibrotic therapy in patients receiving thoracic radiotherapy. Further investigation is needed to validate these findings in patients with worse radiation-induced lung injury than was studied here.",
    "published": "2025-11-06T23:30:04Z",
    "authors": [
      "Zan Hou, Baiqiang Dong, Qiwei Yao, Hualin Chen, Qiuju Shao, Minying Li, Jianyang Wang, Keying Chen, Zhengfei Zhu, Fang Peng, Shihong Wei, Xiao Hu, Jiancheng Li, Meilian Liu, Bin Xu, Siming Zheng, Nan Bi, Shuohan Zheng, Qingqing Xu, Biqi Chen, Chenfei Wu, Rui Li, Wei Chen, Xin Liu, Yuchen Tian, Xuan Li, Suping Guo, Lei Zhao, Yujia Zhu, Ling Cai, Qiaoqiao Li, Li Li, Huilan Zhang, Chen Hu, Luhua Wang, Qiwen Li, Baoqing Chen, Ming Chen"
    ],
    "doi": "10.1016/S1470-2045(25)00515-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00515-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "6c3275f5-a15f-4e90-a705-e2310b965b91",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial",
    "abstract": "Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically significant improvements in progression-free survival compared with chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations, presenting as new treatment options.",
    "published": "2025-12",
    "authors": [
      "Huiping Li, Jieqiong Liu, Quchang Ouyang, Shusen Wang, Yaxin Liu, Yuee Teng, Xiaojia Wang, Jing Cheng, Zhongsheng Tong, Tao Sun, Min Yan, Xin Zhou, Fanfan Li, Jianyun Nie, Zhi-Ming Shao, Changsheng Ye, Yongsheng Wang, Xiaohong Wu, Zhihua Li, Yudong Wu, Huihua Xiong, Hui Li, Lu Gan, Zhaofeng Niu, Juliang Zhang, Qingyuan Zhang, Yueyin Pan, Xinhong Wu, Yi Zhang, Weimin Xie, Yu Xiao, Jinnan Gao, Huadong Zhao, Yongmei Yin, Zhiying Qian, Sanyuan Sun, Hongwei Zhang, Kun Wang, Jinsong Lu, Yong Li, Xinshuai Wang, Xinfeng Yang, Yuting Wang, Quanren Wang, Erwei Song"
    ],
    "doi": "10.1016/S1470-2045(25)00523-6",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00523-6/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "8cf04d2f-8ab9-4c3f-9229-c86135c62fc9",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial",
    "abstract": "In this exploratory, long-term analysis, extended adjuvant metronomic capecitabine provided durable disease-free survival benefit in early triple-negative breast cancer, although the findings should be interpreted with caution given the post-hoc nature of the analysis. Patients with FOXC1-high tumours showed a survival advantage with capecitabine versus observation; if this finding is validated, FOXC1-driven patient selection might be useful to optimise therapeutic responses.",
    "published": "2025-12",
    "authors": [
      "Jing Yuan, Xi-Wen Bi, Xin Hua, Heng Huang, Li Cai, Li Zhao, Qian-Jun Chen, Xin-Xin Chen, Xu-Lin Wang, Ying Lin, An-Qing Zhang, Yong-Yi Zhong, Fei Xu, Jia-Jia Huang, Xin An, Yan-Xia Shi, Xi Wang, Shu-Sen Wang, Cong Xue, Zhong-Yu Yuan"
    ],
    "doi": "10.1016/S1470-2045(25)00545-5",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00545-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "37d0d332-6e03-4e2a-bbe5-0e71cfa14aad",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials",
    "abstract": "With adequate follow-up, distant disease-free survival is a robust surrogate endpoint for predicting final overall survival outcomes in neoadjuvant RCTs for early breast cancer in most contexts. However, the distant disease-free survival surrogacy appears to be weak for the hormone receptor-positive and HER2-negative and for the hormone receptor-positive and HER2-positive molecular subtypes. These latter findings warrant further investigation in more recent RCTs enrolling higher-risk patient populations.",
    "published": "2025-12",
    "authors": [
      "Fabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, Isabella Sala, Eleonora Pagan, Christine Solbach, Michael Untch, Carsten Denkert, Vincenzo Bagnardi, Laura Pala, Peter A Fasching, Andreas Schneeweiss, Hans-Joachim Lück, Giuseppe Viale, Tommaso De Pas, Marion van Mackelenbergh, Jens Huober, Volkmar Müller, Theresa Link, Thomas Karn, Mattea Reinisch, Frederik Marmé, Vesna Bjelic-Radisic, Christian Schem, Andreas Hartkopf, Elmar Stickeler, Claus Hanusch, Jens-Uwe Blohmer, Tanja Fehm, Kerstin Rhiem, Richard Gelber, Sibylle Loibl"
    ],
    "doi": "10.1016/S1470-2045(25)00546-7",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00546-7/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "ba333c42-9291-4ef2-a8a0-a576fdfba981",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study",
    "abstract": "At final analysis, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement compared with sorafenib, with manageable safety. The extended follow-up further confirmed the benefit-to-risk profile of camrelizumab plus rivoceranib, supporting the combination as a new first-line treatment option for unresectable hepatocellular carcinoma.",
    "published": "2025-12",
    "authors": [
      "Shukui Qin, Shanzhi Gu, Stephen L Chan, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Li Xu, Xianglin Yuan, Da Li, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Jinghua Du, Wei Shi, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel, CARES-310 Study Group"
    ],
    "doi": "10.1016/S1470-2045(25)00543-1",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00543-1/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "51ea1a97-a0e5-4b5d-aa2f-1f14036a7b30",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial",
    "abstract": "In pMMR/MSS stage II–III rectal cancer, total neoadjuvant therapy followed by non-operative management allows organ preservation in some patients without compromising distant relapse-free survival, supporting non-operative management as a treatment option in clinical practice.",
    "published": "2025-12",
    "authors": [
      "Alessio Amatu, Giorgio Patelli, Maria Giulia Zampino, Francesca Bergamo, Stefania Mosconi, Federica Tosi, Davide Ciardiello, Sara Lonardi, Giorgia Negrini, Daniela Sibio, Marianna Alessandra Gerardi, Sara Galuppo, Francesco Romeo Filippone, Pietro Carnevali, Simona Borin, Pierluigi Pilati, Elia Poiasina, Erica Bonazzina, Lorenzo Gervaso, Enzo Mammano, Francesco Bracco, Luca Bergamaschi, Gaya Spolverato, Matteo Origi, Uberto Fumagalli Romario, Gianluca Mauri, Nicola Fazio, Edoardo Forti, Giuseppe De Roberto, Chiara Cristofori, Cesare Burti, Luigi Asmundo, Luigi Funicelli, Gaetano Ramondo, Pietro Andrea Bonaffini, Sara Mariano, Luca Lazzari, Silvia Ghezzi, Claudio Isella, Daniela Cantarella, Maria Costanza Aquilano, Luca Bottiglieri, Emanuela Bonoldi, Massimiliano Mutignani, Valter Torri, Enzo Medico, Alberto Bardelli, Silvia Marsoni, Angelo Vanzulli, Mauro Filippo Palazzi, Giovanni Carlo Ferrari, Katia Bencardino, Andrea Sartore-Bianchi, Salvatore Siena"
    ],
    "doi": "10.1016/S1470-2045(25)00542-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00542-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "fa079e97-fb4d-46b4-b73b-091181d39fef",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial",
    "abstract": "Our study met the primary endpoint, showing antitumour activity (clinical complete response rates) and a manageable safety profile for ezabenlimab and mDCF induction when given with INRT in patients with locally advanced SCAC, enabling personalised INRT, and supporting phase 3 trials of this treatment in patients with stage 3 SCAC.",
    "published": "2025-11-04T23:30:01Z",
    "authors": [
      "Stefano Kim, Jihane Boustani, Soledad Iseas, Dewi Vernerey, Ludovic Evesque, Laurent Quero, Francois Ghiringhelli, Clélia Coutzac, Olivier Bouché, Benoist Chibaudel, Chloé Vernet, Angélique Vienot, David Tougeron, Thierry Nguyen, Magali Rebucci-Peixoto, Aurélia Meurisse, Sarah Chennoufi, Christophe Maritaz, Christophe Borg, INTERACT-ION Study Team"
    ],
    "doi": "10.1016/S1470-2045(25)00605-9",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00605-9/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "cfe0cc7b-ee4b-46eb-aa77-9bac48a7aeda",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group",
    "abstract": "The proposed RANO classification for extent of resection could serve as a tool for prognostic stratification. Although associations between survival and extensive surgery are evident sooner in patients with astrocytoma, supramaximal resection also translates into survival benefits for patients with oligodendrogliomas.",
    "published": "2025-12",
    "authors": [
      "Philipp Karschnia, Jacob S Young, Maarten M J Wijnenga, Tommaso Sciortino, Nico Teske, Alba Corell, Arthur Wagner, Gilbert Youssef, Yae Won Park, Levin Häni, Stephanie T Jünger, Antonio Dono, Felix Ehret, Eduardo E Mendoza Mireles, Nicolas Neidert, Francesco Bruno, Chad A Tuchek, Thijs van der Vaart, Marco Rossi, Marco Conti Nibali, Lorenzo Gay, Alfred Gramelt, Nitin Tandon, Sung Soo Ahn, Jong Hee Chang, Michael Weller, Arnaud J P E Vincent, Roland Goldbrunner, Daniel P Cahill, Raymond Y Huang, Andreas Raabe, Bernhard Meyer, Juergen Beck, Annette M Molinaro, Susan M Chang, Michael A Vogelbaum, Roberta Rudà, Einar O Vik-Mo, Jorg Dietrich, Yoshua Esquenazi, Stefan J Grau, Patrick Y Wen, Asgeir S Jakola, Oliver Schnell, Lorenzo Bello, Martin J van den Bent, Shawn Hervey-Jumper, Mitchel S Berger, Joerg-Christian Tonn"
    ],
    "doi": "10.1016/S1470-2045(25)00534-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00534-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "8e1933bd-13f3-4ff9-96de-5ad543809377",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial",
    "abstract": "MB-FUS plus temozolomide is a safe combinatorial therapeutic approach for individuals with high-grade glioma, with the potential to improve survival and enable non-invasive plasma biomarker-based disease surveillance (sono-liquid biopsy), warranting randomised controlled trials.",
    "published": "2025-12",
    "authors": [
      "Graeme F Woodworth, Pavlos Anastasiadis, Ahmad Ozair, Jeremi Chabros, Chetan Bettegowda, Chixiang Chen, Jakob V E Gerstl, Christopher Douville, Rania A Mekary, Timothy R Smith, Ying Meng, Cynthia Hawkins, Christopher B Pople, Agessandro Abrahao, Maheleth Llinas, Chinthaka Heyn, Adomas Bunevicius, Ali R Rezai, Anna J S Ball, Kaitlyn Henry, Arjun Sahgal, Erickson Torio, Haoyu Ren, Haroon Ahmad, Harshit Arora, Howard Eisenberg, James Perry, Jeffrey S Carpenter, Kullervo Hynynen, Lily C Pham, Mary Beth Anketell, Mary Jane Lim-Fat, Zhiyuan Xu, Christopher P Cifarelli, Jason P Sheehan, Nathan J McDannold, Dheeraj Gandhi, Alexandra J Golby, Nir Lipsman"
    ],
    "doi": "10.1016/S1470-2045(25)00492-9",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00492-9/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "75a565a9-33c5-49aa-94de-ca32c7ec4a3f",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial",
    "abstract": "Vorasidenib reduced tumour growth rate and improved seizure control compared with placebo, with no observed negative effects on HRQOL or neurocognition. Additional follow-up supported the robustness of progression-free survival and time to next intervention in patients with grade 2 IDH1/2-mutant diffuse glioma. These findings support the use of vorasidenib in patients with grade 2 IDH1/2-mutant gliomas who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
    "published": "2025-10-29T23:30:02Z",
    "authors": [
      "Timothy F Cloughesy, Martin J van den Bent, Mehdi Touat, Deborah T Blumenthal, Katherine B Peters, Benjamin M Ellingson, Jennifer L Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P Mason, Francois Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F Hottinger, Yoshiki Arakawa, Juan M Sepulveda, Wolfgang Wick, Riccardo Soffietti, James Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth Maher, Andrew Bottomley, Adriana E Tron, Denise Yi, Dan Zhao, Shuchi S Pandya, Lori Steelman, Islam Hassan, Patrick Y Wen, Ingo K Mellinghoff, INDIGO trial investigators"
    ],
    "doi": "10.1016/S1470-2045(25)00472-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00472-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "591fb1ef-fb6a-4b34-9d62-f1b2f4d12a4e",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Articles] Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study",
    "abstract": "This study met its primary endpoint, showing high clinical activity of pembrolizumab plus lenvatinib, but with substantial toxicity, in patients with pleural mesothelioma who had progressed after first-line nivolumab plus ipilimumab. This drug combination is promising for future studies in pleural mesothelioma.",
    "published": "2025-12",
    "authors": [
      "Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A Burgers, Cornedine J de Gooijer"
    ],
    "doi": "10.1016/S1470-2045(25)00514-5",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00514-5/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "822bac38-c01d-4089-ba17-4e21c0a80177",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[The Lancet Oncology Commission] The human crisis in cancer: a Lancet Oncology Commission",
    "abstract": "Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care. Despite overall survival outcomes improving, the systems designed to deliver care increasingly fall short in addressing the emotional, relational, and existential dimensions of cancer. Although examples of compassionate and attentive care can be found in every setting, patients and families across global contexts continue to report being unheard, unsupported, and, at times, actively harmed by care structures that prioritise technical precision over human presence.",
    "published": "2025-11-02T23:30:02Z",
    "authors": [
      "Gary Rodin, Amalya Feldman, Dario Trapani, Mac Skelton, Karla Unger-Saldaña, Beverley Essue, Rille Pihlak, Catherine Walshe, William E Rosa, Matthew P Banegas, Miguel Zambrano-Lucio, Rawaz Salah Daood, Ajay Aggarwal, Omar Dewachi, Gilla K Shapiro, Murallitharan Munisamy, Harenthri Devy Alagir Rajah, Shrikant Atreya, Vijay Shree Dhyani, Yek-Ching Kong, Mebin Mathew, Carol Y Ochoa-Dominguez, Arathi Prahallada Rao, Seema Rajesh Rao, Srinagesh Simha, Nancy Preston, Wendy Wing Tak Lam, Hanae Davis, Camilla Zimmermann, Eve Namisango, Christian Ntizimira, Elizabeth Smyth, Madeline Li, Naveen Salins, Nirmala Bhoo-Pathy, Richard Sullivan"
    ],
    "doi": "10.1016/S1470-2045(25)00530-3",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00530-3/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "8f5a6552-193c-44ec-8f1c-6a59df9077ce",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Review] Neurocognitive outcomes in patients with brain metastases: a systematic review",
    "abstract": "Multimodality therapy, including surgery, radiotherapy, and systemic therapy, has significantly improved overall survival for patients with brain metastases. However, treatment-related neurocognitive sequelae remain a major challenge in survivorship. Although advances in radiotherapy delivery techniques have reduced toxicity, the potential interaction with chemotherapy, targeted therapy, and immunotherapy, and the consequent effect on neurocognitive outcomes is poorly characterised. We conducted a systematic review of clinical trials reporting neurocognitive endpoints in patients with brain metastases receiving radiotherapy with or without other concurrent systemic therapies.",
    "published": "2025-12",
    "authors": [
      "Tarek Bou Dargham, Sebastian F Winter, Kristen Batich, Karin Gehring, Michael W Parsons, Jorg Dietrich, Trey Mullikin, Zachary J Reitman, Scott R Floyd, John P Kirkpatrick, Paul W Sperduto, Jona Hattangadi-Gluth, Helen A Shih, Paul D Brown, Minesh Mehta, Erik P Sulman, Katherine B Peters, Eugene J Vaios"
    ],
    "doi": "10.1016/S1470-2045(25)00525-X",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00525-X/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "afd0bda7-3cb6-4d1a-9b0c-98517e6a41f7",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Policy Review] SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials",
    "abstract": "Standardising the implementation of patient-reported outcomes (PROs) in clinical trials is crucial for evaluating the benefits and risks of cancer treatments. The Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI) has developed 146 consensus-based recommendations for designing, analysing, interpreting, and presenting PROs in cancer clinical trials. This initiative, undertaken from 2021 to 2025, involved experts, including statisticians, PRO measurement experts, clinicians, and patient representatives from 41 organisations representing regulatory agencies, academia, the pharmaceutical industry, health–technology assessment bodies, and patient advocates.",
    "published": "2025-12",
    "authors": [
      "Cecilie D Amdal, Ragnhild S Falk, Ahu Alanya, Michael Schlichting, Satrajit Roychoudhury, Vishal Bhatnagar, Lisa M Wintner, Antoine Regnault, Anders Ingelgård, Corneel Coens, Saskia le Cessie, Bernhard Holzner, Jane Chang, Martin Taphoorn, Paul Cislo, Johannes M Giesinger, Joseph C Cappelleri, Vivek Pawar, Silene ten Seldam, Elektra J Papadopoulos, Melanie J Calvert, Kenth L Joseph, Andrew Bottomley, Ingolf Griebsch, Juan I Arraras, Guro L Astrup, Ethan Basch, Andrej Belančić, Michael Brundage, Alicyn Campbell, Khadija Rerhou Rantell, Kim Cocks, Nathan Cherny, Sonya Eremenco, Montse Ferrer, Mallorie H Fiero, Christoph Gerlinger, Els Goetghebeur, Ulrich Grouven, Alexandra Lauer, Olalekan Lee Aiyegbusi, Abigirl Machingura, Junki Mizusawa, Geert Molenberghs, Morten Aa Petersen, Jaap C Reijneveld, Jolie Ringash, Gerhard Rumpold, Claudia Rutherford, Chantal Quinten, Kavita Sail, Maxime Sasseville, Willi Sauerbrei, Anja Schiel, Ashley W Smith, Claire Snyder, Galina Velikova, Xin S Wang, Kristin Bjordal, Madeline Pe, SISAQOL-IMI Consortium"
    ],
    "doi": "10.1016/S1470-2045(25)00520-0",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00520-0/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  },
  {
    "id": "a7b220e8-526d-4853-ab5d-c250b63d02c3",
    "source_feed": "https://www.thelancet.com/rssfeed/lanonc_current.xml",
    "journal": "The Lancet Oncology",
    "title": "[Policy Review] The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus",
    "abstract": "The Lucerne Toolbox 3 initiative addresses the pressing need for evidence-based integration of digital health and artificial intelligence (AI) technologies in early breast cancer care. The multidisciplinary consortium identified and prioritised 15 crucial medical knowledge gaps across the patient journey, from diagnosis to treatment and survivorship, using a modified Delphi consensus process with 112 unique members from 27 countries and 16 medical societies, trial groups, and patient organisations.",
    "published": "2025-12",
    "authors": [
      "André Pfob, Katja Pinker, Ines Vaz-Luis, Antonio Di Meglio, Maria João Cardoso, Giuseppe Curigliano, Oreste Davide Gentilini, Günther Gruber, Nik Hauser, Jörg Heil, Orit Kaidar-Person, Michael Knauer, Han-Byoel Lee, Sae Byul Lee, Sherene Loi, Meinrad Mannhart, Stella Mastora, Icro Meattini, Rosa Di Micco, Aurelia Noske, Fedro Alessandro Peccatori, Fiorita Poulakaki, Mattea Reinisch, Isabel T Rubio, Charlie Swanton, Christoph Tausch, Marie-Jeanne Vrancken Peeters, Jong Han Yu, Walter Paul Weber, Norman Zerbe, Philip Poortmans, Carsten Denkert, Ritse Mann, Suzette Delaloge, Peter Dubsky, Toolbox 3 Consortium"
    ],
    "doi": "10.1016/S1470-2045(25)00463-2",
    "link": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext?rss=yes",
    "raw_entry_keys": [
      "author",
      "author_detail",
      "authors",
      "dc_identifier",
      "dc_source",
      "id",
      "link",
      "links",
      "prism_endingpage",
      "prism_issueidentifier",
      "prism_number",
      "prism_publicationdate",
      "prism_publicationname",
      "prism_section",
      "prism_startingpage",
      "prism_volume",
      "summary",
      "summary_detail",
      "title",
      "title_detail",
      "updated",
      "updated_parsed"
    ]
  }
]